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Diverse heterozygous mutations of bone morphogenetic receptor type II (BMPR-II) underlie the inherited form
of the vascular disorder primary pulmonary hypertension (PPH). As yet, the molecular detail of how such
defects contribute to the pathogenesis of PPH remains unclear. BMPR-II is a member of the transforming
growth factor-b cell signalling superfamily. Ligand binding induces cell surface receptor complex formation
and activates a cascade of phosphorylation events of intracellular intermediaries termed Smads, which
initiate transcriptional regulation. Some 30% of PPH-causing mutations localize to exon 12, which may be
spliced out forming an isoform depleted of the unusually long BMPR-II cytoplasmic tail. To further elucidate
the consequences of BMPR2 mutation, we sought to characterize aspects of the cytoplasmic domain
function by seeking intracellular binding partners. We now report that Tctex-1, a light chain of the motor
complex dynein, interacts with the cytoplasmic domain of BMPR-II and demonstrate that Tctex-1 is
phosphorylated by BMPR-II, a function disrupted by PPH disease causing mutations within exon 12. Finally
we show that BMPR-II and Tctex-1 co-localize to endothelium and smooth muscle within the media of
pulmonary arterioles, key sites of vascular remodelling in PPH. Taken together, these data demonstrate a
discrete function for the cytoplasmic domain of BMPR-II and justify further investigation of whether the
interaction with and phosphorylation of Tctex-1 contributes to the pathogenesis of PPH.
INTRODUCTION
The transforming growth factor beta (TGF-b) superfamily of
cytokines includes bone morphogenetic proteins (BMPs),
activins and transforming growth factors that each play a
complex and multifunctional role in the regulation of cell
proliferation, differentiation and apoptosis during embryogen-
esis and throughout adult life (1).
The TGF-b cytokines signal through a cooperative ligand-
binding mechanism, which initiates signalling by binding to a
type I (e.g. BMPRIA/IB) and type II (e.g. BMPR-II) serine/
threonine kinase receptor on the cell surface (2,3).
Phosphorylated receptor kinases then propagate intracellular
signalling via intermediary Smad molecules. Activated Smad
complexes translocate to the nucleus and in conjunction with
nuclear cofactors, result in transcriptional regulation of target
genes. Although the Smad family of signalling molecules has
been extensively characterized, BMP-activated Smad-indepen-
dent pathways have also been identified, including members of
the mitogen-activated protein kinase (MAPK) pathways,
notably p38MAPK (1,4).
Heterozygous mutations identified in BMPR2, encoding a
type II BMP receptor, have been associated with the human
disease primary pulmonary hypertension (PPH) (MIM 178600)
(5–7). This lethal vascular disorder is characterized by the
obstruction and occlusion of pulmonary arterioles through
proliferation and migration of endothelial and smooth muscle
cells, leading to a sustained elevation of pulmonary arterial
pressure. PPH is usually fatal, typically as a consequence of
right heart failure (8).
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The gene BMPR2 is located on chromosome 2q33 (9,10) and
encodes a polypeptide of 1038 amino acids. The mature protein
comprises an extracellular ligand binding domain and an
intracellular serine/threonine kinase domain, both linked
through a single transmembrane domain. BMPR-II has a long
carboxy terminal tail (508 amino acids), a feature unique
amongst TGF-b receptors. This cytoplasmic region comprises
almost 50% of the protein, encoded by exon 11 (amino acids
509–529), exon 12 and exon 13 (amino acids 955–1038), yet
is of unknown function (11,12). A short isoform of only 530
amino acids, the result of a splice variant which lacks exon 12,
is also capable of phosphorylating both the Smads and
p38MAPK (12,13). Northern blot and RT–PCR of human tissue
demonstrate both short and long transcripts to be ubiquitously
expressed (J.A. Flanagan et al., unpublished data).
Defects in BMPR2 have been reported in at least 50% of
probands with familial PPH, and are varied in form and
predicted impact on BMPR2 transcripts. The majority of PPH
disease-causing mutations are nonsense or frameshift and many
predict premature transcript truncation. The remainder (26%)
alter highly conserved amino acids within BMPR-II domains of
known function (14). At least in vitro, different mutations lead
to heterogeneous functional defects, which include the
intracellular retention of the mutant receptor and disruption
of Smad-mediated signalling capacity (15). However, we
have demonstrated that all deleterious BMPR2 mutations lead
to constitutive activation of p38MAPK (16). Whilst these
in vitro observations identify aberrant cellular events, it remains
unclear whether they are consequent upon BMPR-II haploin-
sufficiency or the result of a dominant negative effect and
furthermore how such defects contribute to the pathogenesis
of PPH.
At least a third of pathogenic mutations in BMPR2 are
located within the cytoplasmic domain (14) (www.pphgenes.
net). These defects would be unlikely to impact on the splicing
of exon 12, nor the generation of the short isoform, findings
that imply a specific functional requirement for the long
cytoplasmic tail of this type II receptor. In this study we sought
to investigate the role and function of the large cytoplasmic
domain of BMPR-II. Using a yeast two-hybrid screen and in
vitro biochemical assays, we describe an interaction between
the cytoplasmic tail of BMPR-II and Tctex-1, a 14 kDa light
chain of the cytoplasmic dynein complex. Furthermore, we
demonstrate that the ability to bind and phosphorylate dynein
differs between the short and long isoforms of BMPR-II and is
severely compromised by pathogenic mutations underlying
PPH. Finally, we demonstrate co-localization of both BMPR-II
and Tctex-1 within the pulmonary vascular endothelial and
smooth muscle cells, both prominent sites of pathological
remodelling in PPH.
RESULTS
Identification of Tctex-1 as an interacting protein
with BMPR-II
The Gal4 yeast two-hybrid system was used to screen a human
lung cDNA library for proteins that interacted with BMPR-II.
A fragment of BMPR-II (amino acids 209–1038) was used as
bait, with the inclusion of the kinase domain (amino acids
209–508) as a positive control to identify known binding
partners. A total of 40 positive clones, as determined by their
ability to grow in the absence of adenine and histidine and
activate the lacZ gene were identified. Of these, three contained
TGF-bRI, a known interactor with BMPR-II in yeast (3). Two
positive clones contained inserts of unknown function and
await characterization. The remainder represented inserts com-
prising the entire open reading frame, albeit with variable
lengths of untranslated sequence, of a known gene encoding
Tctex-1, a 14 kDa dynein light chain. Cytoplasmic dynein, a
molecular motor protein structured around two heavy chains,
two intermediate chains and a variable number of light–
intermediate and light chains, is responsible for the retrograde
transport of protein cargo along the microtubular network (17).
Refinement of the interaction between Tctex-1 and
BMPR-II by the yeast two hybrid system
The interaction between BMPR-II and Tctex-1 was confirmed
by its reconstitution in an in vivo yeast growth assay.
Additionally, the inability of yeast expressing Tctex-1 and
two randomly chosen transcripts, lamin A and SREBP1a, to
grow on selective media suggested that the interaction with
BMPR-II was both real and specific.
To determine the region of interaction with BMPR-II we
designed four constructs, labelled B–E, encoding truncated and
overlapping products of Tctex-1. Each of these constructs, and
full-length Tctex-1 (construct A), was tested independently for
interaction with BMPR-II. On selective media, growth of yeast
containing BMPR-II was only observed when co-transformed
with constructs A and E (Fig. 1). These data indicate that Tctex-1
interacts with BMPR-II at its carboxy terminal end. This 37
amino acid region of the light chain bears consensus sequences
for casein kinase II and protein kinase C as well as clusters of
serine residues reminiscent of the SSxS motif found in Smads
phosphorylated by receptors of the TGF-b family (18).
An analysis of the interaction between BMP
receptors and Tctex-1 by in vitro binding assays
To substantiate the interaction between BMPR-II and Tctex-1
in vitro, GST pull-down assays were performed. A fusion
protein of GST and full-length Tctex-1 (GST-Tctex1) was
tested against radiolabelled in vitro translations of both the
long isoform (LF) of BMPR-II, containing the exon 12
encoded region and the short form (SF) lacking exon 12. In
addition, the kinase (KD) and cytoplasmic domains (CD) of
BMPR-II expressed as independent domains were similarly
analysed to determine the domain responsible for binding
Tctex-1. Following incubation with GST-Tctex1, both isoforms
of BMPR-II were found to interact with the fusion product
but not GST alone. The experiment was repeated five times
and, in each case, the binding affinity of the SF for Tctex-1 was
markedly lower than the LF. The kinase domain was not
capable of binding Tctex-1 whereas the cytoplasmic region
demonstrated a high affinity for the light chain (Fig. 2A). The
specificity of the interaction between these proteins was
supported not only by the absence of binding to the kinase
domain of BMPR-II, but also by the observation that the
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related TGF-b type I receptor, ALK-1 failed to interact with
GST-Tctex1 (data not shown).
We next sought to determine whether the type I receptors,
BMPRIA and -IB, which have been shown to complex with
BMPR-II in vitro, were also capable of interacting with Tctex-1
(Fig. 2B) (1). The ability of both to bind indicates that type I
BMP receptors can also associate with this light chain.
Effects of PPH causing BMPR2 mutation on
interaction with Tctex-1
The cytoplasmic domain construct was subjected to site-
directed mutagenesis to reproduce three truncating mutations
previously identified in subjects with familial and sporadic PPH
(14). Two mutations, designated 2292insA and 2386delG,
create frameshifts of the open reading frame at the nucleotide
positions indicated and result in premature protein truncation
after the addition of an aberrant series of amino acids. The third
mutation, R899X, causes truncation by the replacement of the
native arginine residue with a premature stop codon at amino
acid position 899. The ability of these mutant constructs to bind
Tctex-1, assessed by the GST pull-down assay, was consistent
with the demonstrated binding affinity of the wild-type
cytoplasmic domain (Fig. 3A). As before, these experiments
were repeated to ensure reproducibility. Varying degrees of
truncation of the terminal end of the cytoplasmic tail and the
removal of the region encoded by exon 13 of the gene do not
cause a reduction in binding affinity. These findings, together
with those of the LF and SF, suggest that the region of the
receptor capable of maintaining high levels of interaction with
Tctex-1 extends from amino acids 509–764 (Fig. 3B).
Phosphorylation of Tctex-1 by wild-type and
mutant BMPR-II
As the BMP receptor complex is known to initiate signalling
events by activating intermediaries such as Smad proteins
through phosphorylation, we investigated whether BMPR-II
was capable of activating Tctex-1 in a similar manner. The two
isoforms of wild-type BMPR-II and three LF constructs
comprising one kinase domain substitution (D485G), a nonsense
(R899X) and a missense mutation (R899P) within the cyto-
plasmic domain were used in a kinase assay with GST fused
Tctex-1. The mutation, R899P, represents the only missense
variant observed in exon 12 of BMPR2 thus far (M. Sankelo
et al., submitted for publication). The BMPR-II LF strongly
phosphorylated Tctex-1, whereas phosphorylation by the SF was
at approximately a third of this level. The kinase mutant
abrogated phosphorylation entirely and the distal cytoplasmic
domain truncation reduced the efficiency of the process to less
than 5% of LF activity (Fig. 4). Interestingly, the amino acid
substitution, R899P, also abolished the ability of the receptor to
phosphorylate Tctex-1 (data not shown). These data are the first
to provide evidence of a differential function between the two
isoforms of BMPR-II and suggest that the LF is more efficient at
phosphorylating substrate such as Tctex-1.
Figure 1. Truncation mapping of the Tctex-1 domain interacting with BMPR-II. Five combinations of Tctex-1 constructs (A–E), fused to the Gal4 activation
domain in pACT2 were individually transformed into the PJ69-4a yeast strain along with the BMPR-II bait construct. Co-transformants were streaked onto
SD media containing (þ) or lacking () the amino acids adenine and histidine. An interaction between the fusion proteins results in the transcription of the reporter
genes, permitting growth. Levels of growth are indicated (þþ¼ strong/¼ none). Only constructs A and E interact with BMPR-II, suggesting that the domain of
interaction in Tctex-1 is at its C-terminal end.
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Immunolocalization of BMPR-II and Tctex-1 in the lung
To determine the expression patterns of BMPR-II and Tctex-1,
immunostaining was performed on normal lung sections.
BMPR-II staining was demonstrated within endothelial cells
lining pulmonary arteries and arterioles, in vascular smooth
muscle cells and within the alveolar wall as reported previously
(Fig. 5A and D) (19). Tctex-1 immunolocalized to endothelial
and smooth muscle cells with a similar distribution pattern to that
seen with the BMPR-II antibody (Fig. 5B and E). Both proteins
displayed high levels of expression in cells comprising capillaries
in the alveolar walls (Fig. 5G and H). Co-incubation of the Tctex-
1 antibody, in both pulmonary arterioles and parenchyma, with a
ten-fold excess of blocking peptide produced no staining,
confirming its specificity (Fig. 5C, F and I).
DISCUSSION
To identify proteins that interact with the cytoplasmic domain
of BMPR-II, we performed a yeast two-hybrid screen of a lung
cDNA library. The strongest protein interactor, and the most
frequently observed, was Tctex-1, a 14 kDa light chain of
dynein.
Cytoplasmic dynein is a retrograde microtubule motor that
is required in a variety of cellular functions including mitotic
cell division, positioning of cellular organelles and intracellular
targeting of proteins (17). This multimeric complex is com-
posed of two heavy chains with force-generating ATP-ase
activity and a variety of intermediate and light chains (20).
There is likely to be considerable subunit heterogeneity in
different complexes as at least three heavy chains, five inter-
mediate chains and three classes of light chains (LC8, LC7/
roadblock, Tctex-1/Tctex-2) have been described, many of
which have varied cellular expression patterns (20–22). Several
of the intermediate and light chains are involved in cargo-
binding activities, predominantly in concert with an accessory
protein, dynactin, which associates with the IC74 class of
intermediate chains (23). However, light chains can act as
specific and direct adaptors for cargo, as demonstrated
by Tctex-1, which interacts with and translocates the photo-
receptor rhodopsin along microtubules by binding to
its cytoplasmic tail (24). The TGF-b receptor complex has
Figure 2. In vitro analyses of the interaction between Tctex-1 and the BMP receptors. (A) Lanes 1–4 represent 35S-labelled, in-vitro translated products of the long
isoform (LF), the short isoform (SF), the kinase domain (KD) and the cytoplasmic domain (CD) of BMPR-II. The amount loaded on these lanes was 10% of that
incubated with GST alone (lane 5) or GST-Tctex1 (lanes 6–8), immobilized on glutathione–Sepharose beads. Proteins were detected by autoradiography. GST
protein alone did not bind the LF (lane 5) whereas GST–Tctex1 interacted with the LF (lane 6), SF (lane 7) and the CD (lane 9) of BMPR-II. (B) The type I
BMP receptors, BMPRIA (IA) and BMPRIB (IB) were in vitro translated (10% of input in lanes 1 and 2) and incubated with purified GST alone (lanes 3 and
5) and GST–Tctex1 (lanes 4 and 6). Both receptors displayed an interaction with Tctex-1. The horizontal arrows to the left of the gels indicate the full-length
protein, the lower bands representing degradation products. Size ladder shown in kDa.
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also been shown to interact with cytoplasmic dynein by
phosphorylating an 11 kDa light chain mLC7-1 on serine
residues, to facilitate its regulation of TGF-b signalling by the
activation of Jun N-terminal kinase (JNK), phosphorylation of
c-Jun, and inhibition of epithelial cell growth (25).
Using a series of truncated constructs we inferred that
Tctex-1 bound BMPR-II at its carboxy terminal end (Fig. 1).
This region of the receptor contains consensus sites for casein
kinase II and protein kinase C. The presence of amino acid
sequence resembling the SSS motif, phosphorylated in
Smads by TGF-b receptors, led us to question whether the
cargo specificity of this light chain might be a consequence of
phosphorylation by BMPR-II and, hence, a mechanism by
which this multi-functional pathway might be regulated (18).
The cargo binding and motor activities of dynein are known
to be highly specific, both spatially and temporally. The
molecular basis of this regulation is not fully understood, yet a
number of mechanisms have been postulated (26). Functional
specificity of dynein is dependent upon the subunit composi-
tion of the complex. For example, Tctex-1, but not its
homologue RP3, is capable of binding the cytoplasmic tail of
rhodopsin, ectopic expression of RP3 displaces Tctex-1 from
the dynein complex, resulting in the disruption of rhodopsin
trafficking (27). Regulation is also achieved by the phosphor-
ylation of dynein subunits by proteins with kinase activity.
Casein kinase II, a serine/threonine kinase, binds and
phosphorylates the intermediate chain, a process believed to
disrupt the association of dynactin with the intermediate chain
and likely to lead to a loss of specificity for cargo recognized by
the dynactin/dynein complex (28).
We next performed in vitro GST pull-down assays using a
GST–Tctex1 fusion protein and a series of wild-type and
mutant BMPR-II constructs. These data demonstrate that
motifs of the cytoplasmic tail, encoded by exon 11 (amino
acids 509–529) and exon 13 (amino acid 530) and present in
the BMPR-II SF, are capable of binding Tctex-1, albeit at a
Figure 3. Interaction between BMPR-II mutants and Tctex-1. (A) In vitro translated, 35S-labelled mutants within the cytoplasmic domain (CD) construct of BMPR-
II (lanes 1–3) were incubated with purified GST-Tctex1 (lanes 4–6). A non-mutated version of the BMPR-II CD similarly translated (not shown) was incubated
with GST alone (lane 7). The left panel shows 10% of the translated product used in the GST pull-down experiment. The right panel shows that all the mutated
forms of the cytoplasmic domain were bound by the GST-Tctex1, whereas the wild-type CD had no affinity for GST alone. The horizontal arrows to the left of the
gels indicate the full-length protein, the lower bands representing degradation products. Size ladder shown in kDa. (B) The filled grey bar represents the exons
encoding the full-length cytoplasmic domain of the receptor. The horizontal black bars depict the two naturally occurring isoforms of BMPR-II as well as the
three tested mutants. The predicted length, in amino acids, is presented in parentheses below the name of the construct. In the case of the mutations resulting
in frameshifts, the expected number of aberrant amino acids added before the presence of a stop codon is indicated by the þ sign. The observed magnitude of
binding between Tctex-1 and the BMPR-II constructs is indicated (þþ¼ strong/þ¼weak).
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much lower affinity than the LF (Fig. 2A). These results
provide, for the first time, a function for the large cytoplasmic
tail domain of BMPR-II, a unique feature of this receptor
within the context of the TGF-b superfamily. Importantly, we
show that constructs of truncating mutations of the cytoplasmic
domain bind Tctex-1, implying that loss of interaction is not
required for the pathogenesis of PPH (Fig. 3A).
Using GST binding assays, we have also demonstrated that
the type I BMP receptors, BMPRIA and -IB, can bind Tctex-1
(Fig. 2B). These interactions might represent a cooperative
intracellular association between independent components of
the BMPR heteromeric complex and Tctex-1 that mirrors the
mechanism of ligand binding by these receptors (29). However,
the structural nature of receptor interaction with Tctex-1 is
likely to differ between members of the receptor superfamily as
the extraordinarily long cytoplasmic domain appears unique to
BMPR-II.
To determine whether Tctex-1 is phosphorylated, and perhaps
activated, by the BMP receptors, we performed in vitro kinase
assays on the two BMPR-II isoforms. The BMPR-II LF
phosphorylated Tctex-1 strongly, whereas SF activity was rela-
tively weak. This was consistent with our premise, on the basis
of the binding data, that the two isoforms of BMPR-II have
distinct cellular profiles and, further, indicated that the entire
cytoplasmic domain was required for effective phosphorylation
of Tctex-1. To confirm this, we repeated the assay with the mutant
receptors, R899X and R899P. The nonsense mutation represents
the most distal truncation observed in a PPH patient whilst the
amino acid substitution is the sole missense mutation thus far
identified within exon 12. These constructs, although capable of
binding Tctex-1, demonstrated a near complete loss of kinase
activity with regard to the light chain. This observation implies
that the intact cytoplasmic domain of the LF generates a three-
dimensional conformation conducive to kinase phosphorylation
activity. Truncation or the substitution of residues such as proline,
an amino acid known to be required for structural integrity,
disrupt this process (Fig. 4). As predicted, we found that a
receptor with a missense mutation in the kinase domain was
incapable of phosphorylating Tctex-1. Based upon these data, we
can hypothesise that truncating mutations located proximal to the
cytoplasmic tail would not be anticipated to bind dynein through
Tctex-1 and we have previously shown that extracellular mutation
within the ligand binding domain generates inactive receptor
complexes incapable of transducing signal (16). Hence, the
majority of pathogenic BMPR2 mutations are predicted to result
in loss of interaction with Tctex-1, suggesting that the functional
relationship between these proteins is likely to be critical in the
dynamic regulation of BMPR-II mediated signalling and hence
of potential significance to the pathogenesis of PPH.
Immunohistochemistry in normal lung sections demonstrated
that BMPR-II and Tctex-1 are expressed in the endothelium
and smooth muscle of pulmonary arteries and arterioles, both
key sites of the pathogenic vascular remodelling observed in
PPH. Co-localization of both proteins was also observed in the
capillaries of the lung parenchyma. The prominence of Tctex-1
staining, in conjunction with the type II receptor, might reflect
the light chain composition of the motor complex in these cell
types and facilitate tissue-specific BMPR-II signalling.
Additionally, the presence of Tctex-1 within cells pathologi-
cally targeted in PPH adds weight to the potential importance
of this protein in combination with BMPR-II in maintaining the
normal pulmonary vascular state (Fig. 5).
Figure 4. Phosphorylation of Tctex-1 by wild-type and mutant BMPR-II. The two isoforms of BMPR-II, LF and SF, a kinase mutant, D485G, and a truncation
mutant of the cytoplasmic domain, R899X, were assayed for the ability to phosphorylate GST–Tctex1. GST–Tctex1 was resolved on a 12% polyacrylamide gel and
incorporated 32P detected by autoradiography. As indicated by the lower panel, equal concentrations of GST–Tctex1, stained with Coomassie blue, were used in
each reaction. The level of phosphorylation, shown by the bar chart, was quantified by a measurement of the 32P count/min. Relative to the empty vector
pcDNA3.0, the long form phosphorylates Tctex-1 strongly, the short form has 30% this level of kinase activity and the mutant receptors are either incapable
of (D485G), or highly deficient in phosphorylating Tctex-1.
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In summary, this study describes a novel interaction between
BMPR-II and a 14 kDa dynein light chain Tctex-1, identified
by means of a yeast two-hybrid screen and confirmed through
in vitro assays. The region of Tctex-1 required for interaction
was refined to the C-terminal 37 amino acids of the protein
whilst the cytoplasmic domain of BMPR-II was demonstrated
to be necessary for this interaction. Functional differences
between the two isoforms of BMPR-II (i.e. SF and LF) were
highlighted by the lower efficiency of the SF BMPR-II receptor
to both bind and phosphorylate the light chain. We report that
cytoplasmic tail mutations in the receptor, known to underlie
PPH, do not adversely affect binding, but prevent phosphor-
ylation of Tctex-1 indicating a structural requirement for
interaction in this important cellular process. The co-expression
of both proteins within endothelial and smooth muscle cells of
pulmonary arterioles emphasizes the importance of this
interaction in the pulmonary vasculature. As the ability of the
dynein motor complex to recognize specific intracellular cargo
is dependent on both the composition and phosphorylation of
its constituent components, the cellular co-localization and
functional interaction between Tctex-1 and BMPR-II supports
the hypothesis that this light chain may be an early mediator of
BMPR-II signalling (Fig. 6). Evidence exists to suggest that
TGF-b signalling can be regulated by the sequestration of
Smads 2, 3 and 4 along the microtubules (30). It is therefore
conceivable that phosphorylation of the Tctex-1 dynein light
chain by the BMPR-II receptor may trigger association with the
motor complex, optimize its affinity for other mediators in the
TGF-b pathway, notably Smad and p38MAPK, facilitating the
transport of these proteins along the microtubule network.
Furthermore, disruption by mutations of BMPR2 impede a
functional consequence of this interaction, namely light chain
Figure 5. Photomicrographs of frozen sections of human lung immunostained with antibodies to BMPR-II (A, D and G) and Tctex-1 (B, E and H) showing
co-localization to smooth muscle (open arrows) and endothelium (arrows) in a muscular pulmonary artery (A and B), in small peripheral arteries (D and E).
High power insets (D and E) show endothelial co-localization. Staining is also apparent in the walls of alveoli (arrows) of lung parenchyma (G and H). The
specificity of the Tctex-1 antibody is demonstrated by the lack of staining, when incubated with blocking peptide, in pulmonary arteries (C) arterioles (F) and
lung parenchyma (I).
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phosphorylation. Taken together these findings imply that the
trafficking of intermediaries of BMPR-II signalling to and from
the cell surface and the perturbation of these processes warrants
further study and specifically in relation to the pathogenesis of
the devastating vascular disorder, PPH.
MATERIALS AND METHODS
Plasmid constructs
All primer sequences used for PCR amplification and in situ
mutagenesis are shown in Table 1. The two isoforms of BMPR-
II, LF and SF, in the expression vector pcDNA3.0 were the kind
gifts of Drs Kohei Miyazono and Petra Knaus, respectively.
The bait construct was generated by PCR amplification through
amino acids 209–1038 using the primers Baitf and Baitr with
the long isoform of BMPR2 cDNA as template. This product
was digested with EcoRI and BamHI and ligated into the same
sites in the plasmid pGBDUc1. Full-length Tctex-1, containing
the open reading frame alone (amino acids 1–113) was also
produced by PCR using the primers Tctex1Af and Tctex1Ar.
The template used was the longest Tctex-1 library clone
isolated in the yeast two-hybrid screen. The deletion constructs
B (amino acids 1–75), C (amino acids 1–43) and D (amino
acids 1–26) were amplified using the primer pairs Tctex1Af
with -Br, -Cr and -Dr, respectively. Construct E (amino acids
18–113) was produced by use of the primers Tctex1Ef and
Tctex1Ar. These products were digested with the restriction
enzymes EcoRI and XhoI and ligated, in the correct frame to
the activation domain of pACT2, the lung cDNA library vector.
The GST fusion construct of Tctex-1 was produced by
generating a PCR product, from the Tctex-1 library clone with
the primers GST-tctex1f and GST-tctex1r, which was ligated
into the plasmid pGEX-4T1 (Amersham-Pharmacia) using the
restriction sites EcoRI and BamHI. The BMPR-II kinase
domain (KD) was created by PCR, using the primers
BMPR2KDf and BMPR2KDr with the LF cDNA as template.
This product was ligated into pcDNA3.0 at the restriction sites
BamHI and XhoI. As the cytoplasmic domain (CD) could not
be directly amplified by PCR, it was constructed in two parts by
taking advantage of a unique HpaI site 930 nucleotides from
the start of the domain. This segment of DNA was amplified
Table 1. Primers used in cloning and mutagenesis
Primer name Sequence
Baitf GATCGAATTCATTGGCCGAGGTCGATATGC
Baitr GATCGGATCCTCACAGACAGTTCATTCCTA
Tctex1Af GATCGAATTCGCATGGAAGACTACCAGGCTGC
GGA
Tctex1Ar GATCCTCGAGTCAAATAGACAGTCCGAAGGCA
Tctex1Br GATCCTCGAGTCCAGCTCCATTCTTCTGCAT
Tctex1Cr GATCCTCGAGGGTCCACTGGTTCACTTTGCT
Tctex1Dr GATCCTCGAGTTCTATAGCCTCTTTTACAAT
Tctex1Ef GATCGAATTCGCAACATTGTAAAAGAGGCTATA
GAA
GST-tctex1f GATCGGATCCATGGAAGACTACCAGGCTGC
GST-tctex1r GATCGAATTCTCAAATAGACAGTCCGAAGG
BMPR2KDf GATCGGATCCGCCACCATGAATCTGAAACTGT
TGGAGCT
BMPR2KDr GATCCTCGAGTCAAATCATCATAAGTTCAGCCA
BMPR2CDHpaIf GATCGGATCCGCCACCATGTGGGAAAGAAACA
AATCTGT
BMPR2CDHpaIr GATCGTTAACACTGTGGTTTCTACCTGCCACA
2292insAf CTTTGAACACCAAAAAATTCAACAAAAGAGCC
CCGGC
2292insAr GCCGGGGCTCTTTTTTTGAATTTTTTGGTGTTC
AAAG
2386delGf GATGAATACAATCAATCAGCAGAACCTCATGTG
2386delGr CACATGAGGTTCTGCTGATTGATTGTATTCATC
Figure 6. Representation of the interaction between BMPR-II and Tctex-1. The type II receptor, within the BMP receptor complex, depicted by the grey bars on the
cell surface, binds Tctex-1 through its cytoplasmic tail. This interaction facilitates the phosphorylation, P, of Tctex-1, in complex with cytoplasmic dynein on the
microtubules, through the kinase domain of BMPR-II. Mutations of BMPR2, shown by the asterisks, prevent phosphorylation of the light chain. When activated by
BMPR-II, Tctex-1 may move along the microtubules and interact with downstream mediators of BMPR-II signalling, for example, Smad1 and P38MAPK.
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using the primers BMPR2CDHpaIf and BMPR2CDHpaIr. The
PCR fragment was digested with BamHI and HpaI and used to
replace the preceding 2455 nucleotides from the LF BMPR2
cDNA insert in pcDNA3.0 to engineer a wild-type cytoplasmic
domain construct. The cytoplasmic domain mutant, R899X,
was produced by ligating the 930 bp PCR product into a full-
length BMPR2 cDNA containing the mutation. Other CD
mutants, 2292insA and 2386delG, were generated by perform-
ing site-directed mutagenesis with the QuickChange kit
(Stratagene) on the wild-type CD construct using the primer
pairs listed in Table 1. All constructs were verified by direct
sequencing on an Applied Biosystems 377 sequencer using the
Applied Biosystems BigDye Terminator sequencing kit
(Perkin-Elmer). The LF mutants, D485G, R899X and R899P
were made as previously described (16).
Yeast two-hybrid screen
The yeast strain PJ69-4a (31) was transformed, in a sequential
manner, with first the bait plasmid and subsequently lung
library cDNA using a protocol devised by Agatep et al. (32).
The yeast strain, containing the bait plasmid, was maintained
by plating onto SD yeast media lacking uracil and transformed
with 60 mg of DNA from an adult lung cDNA library
(Clontech). Interacting clones were selected for by plating the
transformants onto SD/-URA/-LEU/-HIS/-ADE supplemented
with 25mM 3-aminotriazole. To determine the strength of
interaction between positive clones, a beta-galactosidase agar
overlay assay was performed using the method described by
Duttweiler (33). The bait plasmid was removed from the yeast
strain by growth on SD/-LEU containing 1 g/l 5-fluoro-orotic
acid, which negatively selects against plasmids bearing the
uracil encoding gene. The library plasmids were subsequently
isolated using a Zymoprep kit (ZymoResearch). All library
plasmid inserts were sequenced using a primer to the Gal4
activation domain (50TACCACTACAATGGATGATGT-30).
The resultant sequences were checked for homology to known
transcripts in the GenBank database using the BLAST
alogorithm (www.ncbi.nlm.nih.gov/BLAST).
Direct interaction growth assays using this system were
performed by transforming Tctex-1 constructs into yeast
containing the BMPR-II bait and streaking the transformants
onto selective media. Interaction between the clones was
inferred by growth on this media.
GST pull-down assays
The GST-Tctex1 construct was transformed into the E. coli
strain BL21 and expression of the fusion protein induced by the
addition of 0.3mM isopropyl-b-D-thiogalactopyranoside (IPTG)
for 3 h at 37C. After lysing the bacterial cells by sonication, the
GST fusion protein was purified by incubation with washed
glutathione–Sepharose 4B beads (Amersham-Pharmacia) as per
the manufacturer’s protocol. Using the wheat germ TnT T7-
coupled transcription/translation system (Promega), BMPR
proteins were labelled with 35S-methionine and in
vitro translated from the relevant pcDNA3.0 vector following
the manufacturer’s instructions. Between 10 and 20mg of the
purified GST fusion protein was added to 20ml of radiolabelled
protein, 100mM PMSF and protease inhibitor cocktail (Roche)
at a 7 concentration. The final volume was adjusted to 750ml
with NETN buffer (0.5% Nonidet P-40, 1mM EDTA, 20mM
Tris–HCL pH 8, 100mM NaCl). This mixture was rotated at
4C for 90min and subjected to three washes in NETN buffer.
The proteins were boiled for 5min in 2Laemmli buffer to
disassociate them from the beads and resolved on 10%
polyacrylamide gels. Concurrently, a 10% volume of the in
vitro translated protein used in the GST pull-down was similarly
resolved. The gels were stained in Coomassie buffer and
exposed to autoradiograph film for up to 5 days.
In vitro kinase assays
HeLa cells were transfected in 10 cm dishes with 20 mg myc-
BMPR2-pcDNA3.0 wild type using Lipofectamine 2000
(Invitrogen) as per the manufacturer’s protocol. Forty-eight
hours post-transfection, cell protein was harvested using kinase
lysis buffer (50mM Hepes, 100mM NaCl, 5% NP-40, 10mM
EDTA, 1mM PMSF, 2.5mM NaVO4, 50mM NaF, 1mM DTT,
20mM b-glycerolphosphate, 1 mM pepstatin, and 10 mg/ml each
of leupeptin, antipain and aprotinin), incubated on ice for 1 h
followed by centrifugation at 13 000 rpm for 20 minutes at 4C.
Samples were then incubated with antibody [mouse anti-myc
9E10 (Santa Cruz), 1 :50 dilution; mouse anti-HA clone HA-7
(Sigma), 1 :100 dilution] on a rotary mixer for 2 h at 4C. Pre-
washed Protein-G sepharose beads (Amersham) were then
added and the mixture incubated on the rotary mixer overnight
at 4C. Protein–bead complexes were washed three times with
kinase lysis buffer, excluding detergent at 2500 g for 2min at
4C. GST-Tctex1 fusion protein beads were produced as
described above.
Kinase reactions were prepared on ice, comprising 10 ml
BMP receptor kinase protein, 15 ml Tctex-1 substrate protein,
15 ml kinase assay buffer (20mM Tris–HCl, pH7.5, 75mM Na
Cl2, 100mM b-glycerolphosphate, 10mM MgCl2, 10mM
MnCl2, and protease inhibitors as kinase lysis buffer), and
2 mCi of 32P-gATP (Amersham). Reactions were incubated at
30C for 30min and subsequently terminated by boiling for
5min in 5 Laemmli buffer. The protein was resolved on 12%
SDS–PAGE gels, fixed and stained in Coomassie buffer, dried
and put down to autoradiography for 48 h. Phospho-image
analysis was subsequently performed on the specific gel protein
substrate bands.
Tissue preparation and immunohistochemistry
Frozen sections of normal lung tissue were cut at 6mm and fixed
in acetone for 6min at room temperature. Sections were either
incubated with the polyclonal anti-Tctex-1 (kindly donated by
Dr Stephen M. King) or anti-BMPR-II, which was raised
against a peptide corresponding to amino acid residues 185–202
of the 1038-amino acid BMPR-II sequence. Anti-CD31 and
anti-smooth muscle actin (SmA) antibodies (DakoCytomation,
Ely, UK) were used to localize endothelial and smooth muscle
cells, respectively. Primary antibodies were incubated for 1 h at
room temperature. Antigens were visualized with a streptavidin
biotin peroxidase technique in line with the manufacturer’s
recommendation (DakoCytomation, Ely, UK). Positive staining
was visualized with 303 diaminobenzidine, producing a brown
reaction product. The specificity of immunostaining was
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demonstrated by the absence of signal in sections processed
after the omission of primary antibody and by incubation of the
Tctex-1 antibody with a 10-fold excess of blocking peptide.
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